

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 September 2020 (24.09.2020)



(10) International Publication Number
WO 2020/188086 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2020/057794

(22) International Filing Date:
20 March 2020 (20.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
19305345.1 20 March 2019 (20.03.2019) EP
19219691.3 24 December 2019 (24.12.2019) EP

(71) Applicants: **IMCHECK THERAPEUTICS SAS** [FR/FR]; 180 avenue du Prado, 13008 MARSEILLE (FR). **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101, rue de Tolbiac, 75013 PARIS (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -** [FR/FR]; 3, rue Michel Ange, 75016 PARIS (FR). **INSTITUT JEAN PAOLI & IRENE CALMETTES** [FR/FR]; 232 boulevard Sainte- Marguerite, 13009 MARSEILLE (FR). **UNIVERSITÉ D'AIX-MARSEILLE** [FR/FR]; 58 Boulevard Charles Livon, 13007 MARSEILLE (FR).

(72) Inventors: **FOUCHER, Etienne**; 11 rue de la croix, 13007 MARSEILLE (FR). **CANO, Carla**; 88 Bd Sainte Marguerite, 13009 MARSEILLE (FR). **LE, Kieu Suong**; 215 ancien chemin de Cassis, 13009 MARSEILLE (FR). **PASERO, Christine**; 151 chemin Colline Saint Joseph, 13009 MARSEILLE (FR). **OLIVE, Daniel**; Aix Marseille Université - INSERM UMR1068, 27 boulevard Lei Roure, 13009 MARSEILLE (FR).

(74) Agent: **PLASSERAUD IP**; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/188086 A1

(54) Title: ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF

(57) Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.